throbber
 
` HIGHLIGHTS OF PRESCRIBING INFORMATION
`
`These highlights do not include all the information needed to use
`
`AIMOVIG safely and effectively. See full prescribing information for
`AIMOVIG.
`
`AIMOVIGTM (erenumab-aooe) injection, for subcutaneous use
`Initial U.S. Approval: 2018
`
`----------------------------INDICATIONS AND USAGE--------------------------­
`AIMOVIG is a calcitonin gene-related peptide receptor antagonist indicated
`
`for the preventive treatment of migraine in adults (1)
`
`
`---------------------------DOSAGE AND ADMINISTRATION------------------­
` For subcutaneous use only (2.1, 2.2)
`
` Recommended dosage is 70 mg once monthly; some patients may benefit
`
`from a dosage of 140 mg once monthly (2.1)
` The 140 mg dose is administered once monthly as two consecutive
`
`injections of 70 mg each (2.1)
`
`
` The needle shield within the white cap of the prefilled autoinjector and the
`
`
`gray needle cap of the prefilled syringe contain dry natural rubber (a
`
`derivative of latex), which may cause allergic reactions in individuals
`sensitive to latex (2.2)
` Administer in the abdomen, thigh, or upper arm subcutaneously (2.2)
`
`
`
`FULL PRESCRIBING INFORMATION: CONTENTS*
`1
`INDICATIONS AND USAGE
`DOSAGE AND ADMINISTRATION
`2
`
`2.1 Recommended Dosing
`
`Important Administration Instructions
`2.2
`DOSAGE FORMS AND STRENGTHS
`
`CONTRAINDICATIONS
`
`ADVERSE REACTIONS
`
`6.1 Clinical Trials Experience
`
`6.2
`Immunogenicity
`USE IN SPECIFIC POPULATIONS
`8.1
`Pregnancy
`8.2
`Lactation
`8.4
`Pediatric Use
`8.5 Geriatric Use
`
`3
`4
`6
`
`8
`

`
`
`

`
`
`
`
`
` See Dosage and Administration for important administration instructions
`
`(2.2)
`-----------------------DOSAGE FORMS AND STRENGTHS------------------­
` Injection: 70 mg/mL solution in a single-dose prefilled SureClick®
`
`
`autoinjector (3)
` Injection: 70 mg/mL solution in a single-dose prefilled syringe (3)
`
`------------------------------CONTRAINDICATIONS----------------------------­
`None (4)
`------------------------------ADVERSE REACTIONS-----------------------------­
`
`The most common adverse reactions in AIMOVIG clinical studies (occurring
`in at least 3% of treated patients and more often than placebo) are injection
`
`site reactions and constipation (6.1)
`To report SUSPECTED ADVERSE REACTIONS, contact Amgen
`
`
`Medical Information at 1-800-77-AMGEN (1-800-772-6436) or FDA at
`
`
`1-800-FDA-1088 or www.fda.gov/medwatch.
`See 17 for PATIENT COUNSELING INFORMATION and
`
`FDA-approved Patient Labeling.
`
`
`Revised: 5/2018
`
`
`11 DESCRIPTION
`
`12 CLINICAL PHARMACOLOGY
`12.1 Mechanism of Action
`
`12.2 Pharmacodynamics
`
`12.3 Pharmacokinetics
`
`13 NONCLINICAL TOXICOLOGY
`
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`
`14 CLINICAL STUDIES
`
`16 HOW SUPPLIED/STORAGE AND HANDLING
`16.1 How Supplied
`16.2 Storage and Handling
`
`
`17 PATIENT COUNSELING INFORMATION
`
`
`*Sections or subsections omitted from the full prescribing information are
`
`
`not listed
`
`
`

`
`Reference ID: 4264882
`
`
`

`Page 1 of 14
`
`1
`
`EX2238
`Eli Lilly & Co. v. Teva Pharms. Int'l GMBH
`IPR2018-01425
`
`

`


`FULL PRESCRIBING INFORMATION
`
`
`1
`
`INDICATIONS AND USAGE
`
`
`AIMOVIG is indicated for the preventive treatment of migraine in adults.
`
`
`2
`
`DOSAGE AND ADMINISTRATION
`
`
`Recommended Dosing
`2.1
`The recommended dosage of AIMOVIG is 70 mg injected subcutaneously once monthly. Some patients may
`benefit from a dosage of 140 mg injected subcutaneously once monthly, which is administered as two
`consecutive subcutaneous injections of 70 mg each.
`
`If a dose of AIMOVIG is missed, administer as soon as possible. Thereafter, AIMOVIG can be scheduled
`monthly from the date of the last dose.
`
`
`Important Administration Instructions
`2.2
`AIMOVIG is for subcutaneous use only.
`
`The needle shield within the white cap of the AIMOVIG prefilled autoinjector and gray needle cap of the
`AIMOVIG prefilled syringe contain dry natural rubber (a derivative of latex), which may cause allergic
`reactions in individuals sensitive to latex.
`
`AIMOVIG is intended for patient self-administration. Prior to use, provide proper training to patients and/or
`caregivers on how to prepare and administer AIMOVIG using the single-dose prefilled autoinjector or
`single-dose prefilled syringe, including aseptic technique [see Instructions for Use]:
`
`  Prior to subcutaneous administration, allow AIMOVIG to sit at room temperature for at least 30 minutes
`
`
`protected from direct sunlight [see How Supplied/Storage and Handling (16.2)]. Do not warm by using a
`
`heat source such as hot water or a microwave.
`
` Do not shake the product.
`
`
`
`
`
`Inspect visually for particulate matter and discoloration prior to administration [see Dosage Forms and
`Strengths (3)]. Do not use if the solution is cloudy or discolored or contains flakes or particles.
`
` Administer AIMOVIG in the abdomen, thigh, or upper arm subcutaneously. Do not inject into areas where
`
`the skin is tender, bruised, red, or hard.
`
` Both prefilled autoinjector and prefilled syringe are single-dose and deliver the entire contents.
`
`
`3
`
`DOSAGE FORMS AND STRENGTHS
`
`AIMOVIG is a sterile, clear to opalescent, colorless to light yellow solution available as follows:
`Injection: 70 mg/mL in a single-dose prefilled SureClick® autoinjector
`
`
`
`Injection: 70 mg/mL in a single-dose prefilled syringe
`
`
`
`4
`
`CONTRAINDICATIONS
`
`
`None.
`

`
`Reference ID: 4264882
`
`
`

`Page 2 of 14
`
`2
`
`

`


`
`6
`
`
`
` ADVERSE REACTIONS
`
`
`Clinical Trials Experience
`6.1
`Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the
`clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not
`
` reflect the rates observed in clinical practice.
`
`The safety of AIMOVIG has been evaluated in 2,537 patients with migraine who received at least one dose of
`AIMOVIG, representing 2,310 patient-years of exposure. Of these, 2,057 patients were exposed to 70 mg or
`140 mg once monthly for at least 6 months, 1,198 patients were exposed for at least 12 months, and 287 patients
`were exposed for at least 18 months.
`
`In placebo-controlled clinical studies (Studies 1, 2, and 3) of 2,184 patients, 787 patients received at least one
`dose of AIMOVIG 70 mg once monthly, 507 patients received at least one dose of AIMOVIG 140 mg once
`monthly, and 890 patients received placebo during 3 months or 6 months of double-blind treatment [see
`Clinical Studies (14)]. Approximately 84% were female, 91% were white, and the mean age was 42 years at
`study entry.
`
`The most common adverse reactions (incidence ≥ 3% and more often than placebo) in the migraine studies were
`injection site reactions and constipation. Table 1 summarizes the adverse reactions that occurred during the first
`3 months in the migraine studies (Studies 1, 2, and 3).
`Table 1: Adverse Reactions Occurring with an Incidence of at Least 2% for Either Dose of AIMOVIG
`and at Least 2% Greater than Placebo During the First 3 Months in Studies 1, 2, and 3

`AIMOVIG
`
`AIMOVIG
`Placebo
`70 mg Once Monthly
`
`
`
`140 mg Once Monthly
`N = 787
`N = 890
`N = 507
`%
`%
`%
`3
`Injection site reactionsa
`6
`5
`1
`1
`3
`Constipation
`< 1
`
`< 1
`2
`Cramps, muscle spasms
`aInjection site reactions include multiple adverse reactions related terms, such as injection site pain and injection site erythema.
`
`
`Adverse Reaction
`
`In Studies 1, 2, and 3, 1.3% of patients treated with AIMOVIG discontinued double-blind treatment because of
`adverse events. The most frequent injection site reactions were injection site pain, injection site erythema, and
`injection site pruritus.
`
`
`6.2
`
`Immunogenicity
`
`As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation,
`including neutralizing antibodies, is highly dependent on the sensitivity and specificity of the assay.
`Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be
`influenced by several factors including assay methodology, sample handling, timing of sample collection,
`concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies
`to erenumab-aooe in the studies described below with the incidence of antibodies in other studies or to other
`products may be misleading.
`
`The immunogenicity of AIMOVIG has been evaluated using an immunoassay for the detection of binding
`anti-erenumab-aooe antibodies. For patients whose sera tested positive in the screening immunoassay, an in
`vitro biological assay was performed to detect neutralizing antibodies.
`

`
`Reference ID: 4264882
`
`
`

`Page 3 of 14
`
`3
`
`

`


`In controlled studies with AIMOVIG, the incidence of anti-erenumab-aooe antibody development was
`6.2% (48/778) in patients receiving AIMOVIG 70 mg once monthly (2 of whom had in vitro neutralizing
`activity) and 2.6% (13/504) in patients receiving AIMOVIG 140 mg once monthly (none of whom had in vitro
`
`neutralizing activity). The neutralizing anti-erenumab-aooe antibody positive rate may be underestimated
`because of limitations of the assay. Although these data do not demonstrate an impact of anti-erenumab-aooe
`antibody development on the efficacy or safety of AIMOVIG in these patients, the available data are too limited
`to make definitive conclusions.
`
`
`
`8
`
`
`8.1
`
`USE IN SPECIFIC POPULATIONS
`
`Pregnancy
`
`Risk Summary
`There are no adequate data on the developmental risk associated with the use of AIMOVIG in pregnant women.
`No adverse effects on offspring were observed when pregnant monkeys were administered erenumab-aooe
`throughout gestation (see Data). Serum erenumab-aooe exposures in pregnant monkeys were greater than those
`in humans at clinical doses.
`
`In the U.S. general population, the estimated background risk of major birth defects and miscarriage in
`clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. The estimated rate of major birth
`defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates
`reported in women without migraine.
`
`
`Clinical Considerations
`Disease-Associated Maternal and/or Embryo/Fetal Risk
`Published data have suggested that women with migraine may be at increased risk of preeclampsia during
`pregnancy.
`
`Data
`Animal Data
`In a study in which female monkeys were administered erenumab-aooe (0 or 50 mg/kg) twice weekly by
`subcutaneous injection throughout pregnancy (gestation day 20-22 to parturition), no adverse effects on
`offspring were observed. Serum erenumab-aooe exposures (AUC) in pregnant monkeys were approximately 20
`times that in humans at a dose of 140 mg once monthly.
`
`
`8.2
`
`Lactation
`
`Risk Summary
`There are no data on the presence of erenumab-aooe in human milk, the effects on the breastfed infant, or the
`effects on milk production. The developmental and health benefits of breastfeeding should be considered along
`
`with the mother’s clinical need for AIMOVIG and any potential adverse effects on the breastfed infant from
`AIMOVIG or from the underlying maternal condition.
`
`
`8.4
`
`Pediatric Use
`
`Safety and effectiveness in pediatric patients have not been established.
`

`
`Reference ID: 4264882
`
`
`

`Page 4 of 14
`
`4
`
`

`


`
`8.5 Geriatric Use
`Clinical studies of AIMOVIG did not include sufficient numbers of patients aged 65 and over to determine
`whether they respond differently from younger patients. In general, dose selection for an elderly patient should
`be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased
`hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
`
`
`DESCRIPTION
`11
`Erenumab-aooe is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to
`the calcitonin gene-related peptide receptor. Erenumab-aooe is produced using recombinant DNA technology in
`Chinese hamster ovary (CHO) cells. It is composed of 2 heavy chains, each containing 456 amino acids, and 2
`light chains of the lambda subclass, each containing 216 amino acids, with an approximate molecular weight of
`150 kDa.
`
`AIMOVIG (erenumab-aooe) injection is supplied as a sterile, preservative-free, clear to opalescent, colorless to
`light yellow solution for subcutaneous administration. Each 1 mL single-dose prefilled autoinjector and
`single-dose prefilled glass syringe contains 70 mg erenumab-aooe, acetate (1.5 mg), polysorbate 80 (0.10 mg),
`
`and sucrose (73 mg). Enclosed within the autoinjector is a single-dose, prefilled glass syringe. The solution of
`AIMOVIG has a pH of 5.2.
`
`
`12
`
`CLINICAL PHARMACOLOGY
`
`
`
`
`12.1 Mechanism of Action
`Erenumab-aooe is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP)
`receptor and antagonizes CGRP receptor function.
`
`
`12.2 Pharmacodynamics
`In a randomized, double-blind, placebo-controlled study in healthy volunteers, concomitant administration of
`
`erenumab-aooe (140 mg intravenous, single-dose) with sumatriptan (12 mg subcutaneous, given as two 6 mg
`doses separated by one hour) had no effect on resting blood pressure compared with sumatriptan alone.
`AIMOVIG is for subcutaneous use only.
`
`
`12.3 Pharmacokinetics
`Erenumab-aooe exhibits non-linear kinetics as a result of binding to the CGRP receptor. The Cmax mean and
`AUClast mean following subcutaneous administration of a 70 mg once monthly and a 140 mg once monthly
`dose in healthy volunteers or migraine patients are included in Table 2.
`
`Less than 2-fold accumulation was observed in trough serum concentrations (Cmin) for episodic and chronic
`migraine patients following subcutaneous administration of 70 mg once monthly and 140 mg once monthly
`doses (see Table 2). Serum trough concentrations approached steady state by 3 months of dosing. The effective
`half-life of erenumab-aooe is 28 days.
`

`
`Reference ID: 4264882
`
`
`

`Page 5 of 14
`
`5
`
`

`


`
`
`
`Table 2: Pharmacokinetic Parameters of AIMOVIG
`AIMOVIG 70 mg
`AIMOVIG 140 mg
`
`Subcutaneously Once Monthly
`Subcutaneously Once Monthly
`
`
` 6.1 (2.1) mcg/mL
` 15.8 (4.8) mcg/mL
` 505 (139) day*mcg/mL
`159 (58) day*mcg/mL
`
`
`
`
`
`5.7 (3.1) mcg/mL
`
`6.2 (2.9) mcg/mL
`
`
`12.8 (6.5) mcg/mL
`
`14.9 (6.5) mcg/mL
`
`Cmax mean (SD)a,b
`
`AUClast mean (SD)a,b
`
`
` Cmin (SD)
`Episodic migraine
`
`Chronic migraine
`a SD = standard deviation
`
`b from a single-dose study
`
` Absorption
`Following a single subcutaneous dose of 70 mg or 140 mg erenumab-aooe administered to healthy adults,
`median peak serum concentrations were attained in approximately 6 days, and estimated absolute bioavailability
`was 82%.
`
`Distribution
`Following a single 140 mg intravenous dose, the mean (SD) volume of distribution during the terminal phase
`(Vz) was estimated to be 3.86 (0.77) L.
`
`Metabolism and Excretion
`Two elimination phases were observed for erenumab-aooe. At low concentrations, the elimination is
`predominantly through saturable binding to target (CGRP receptor), while at higher concentrations the
`elimination of erenumab-aooe is largely through a non-specific, non-saturable proteolytic pathway.
`
`Specific Populations
`The pharmacokinetics of erenumab-aooe were not affected by age, gender, race, or subtypes of migraine
`spectrum (episodic or chronic migraine) based on population pharmacokinetics analysis.
`Patients with Renal or Hepatic Impairment
`Population pharmacokinetic analysis of integrated data from the AIMOVIG clinical studies did not reveal a
`difference in the pharmacokinetics of erenumab-aooe in patients with mild or moderate renal impairment
`relative to those with normal renal function. Patients with severe renal impairment (eGFR
`< 30 mL/min/1.73 m2) have not been studied. No dedicated clinical studies were conducted to evaluate the
`effect of hepatic impairment or renal impairment on the pharmacokinetics of erenumab-aooe. Renal or hepatic
`impairment is not expected to affect pharmacokinetics of erenumab-aooe.
`Drug Interaction Studies
`P450 Enzymes
`Erenumab-aooe is not metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant
`medications that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.
`Oral Contraceptives
`In an open-label drug interaction study in healthy female volunteers, erenumab-aooe (140 mg subcutaneous,
`single-dose) did not affect the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol
`and norgestimate.
`Sumatriptan
`In a study in healthy volunteers, concomitant administration of erenumab-aooe with sumatriptan had no effect
`on the pharmacokinetics of sumatriptan [see Clinical Pharmacology (12.2)].
`
`

`
`Reference ID: 4264882
`
`
`

`Page 6 of 14
`
`6
`
`

`


`
`13
`
`
`
` NONCLINICAL TOXICOLOGY
`
`
`
`
` 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`Carcinogenesis
`
`The carcinogenic potential of erenumab-aooe has not been assessed.
`
`Mutagenesis
`
`Genetic toxicology studies of erenumab-aooe have not been conducted.
`
`Impairment of Fertility
`Mating studies have not been conducted on erenumab-aooe. No histopathological changes in male or female
`reproductive organs were observed in monkeys administered erenumab-aooe (0, 25, or 150 mg/kg) by
`subcutaneous injection twice weekly for up to 6 months. Serum erenumab-aooe exposures (AUC) at the higher
`dose tested were more than 100 times that in humans at a dose of 140 mg once monthly.
`
`
`
`CLINICAL STUDIES
`14
`The efficacy of AIMOVIG was evaluated as a preventive treatment of episodic or chronic migraine in three
`randomized, double-blind, placebo-controlled studies: two studies in patients with episodic migraine (4 to 14
`migraine days per month) (Study 1 and Study 2) and one study in patients with chronic migraine (≥ 15 headache
`days per month with ≥ 8 migraine days per month) (Study 3). The studies enrolled patients with a history of
`migraine, with or without aura, according to the International Classification of Headache Disorders (ICHD-III)
`diagnostic criteria.
`Episodic Migraine
`Study 1 (NCT 02456740) was a randomized, multi-center, 6-month, placebo-controlled, double-blind study
`evaluating AIMOVIG for the preventive treatment of episodic migraine. A total of 955 patients with a history of
`
`episodic migraine were randomized to receive either AIMOVIG 70 mg (N = 317), AIMOVIG 140 mg
`(N = 319), or placebo (N = 319) by subcutaneous injection once monthly (QM) for 6 months. Patients were
`allowed to use acute headache treatments including migraine-specific medications (i.e., triptans, ergotamine
`derivatives) and NSAIDs during the study.
`The study excluded patients with medication overuse headache as well as patients with myocardial infarction,
`stroke, transient ischemic attacks, unstable angina, coronary artery bypass surgery, or other revascularization
`procedures within 12 months prior to screening.
`
`The primary efficacy endpoint was the change from baseline in mean monthly migraine days over months 4 to
`6. Secondary endpoints included the achievement of a ≥ 50% reduction from baseline in mean monthly
`migraine days over months 4 to 6 (“≥ 50% MMD responders”), the change from baseline in mean monthly
`acute migraine-specific medication days over months 4 to 6, and the change from baseline in mean Migraine
`Physical Function Impact Diary (MPFID) over months 4 to 6. The MPFID measures the impact of migraine on
`everyday activities (EA) and physical impairment (PI) using an electronic diary administered daily. Monthly
`
`MPFID scores are averaged over 28 days, including days with and without migraine; scores are scaled from 0 to
`100. Higher scores indicate worse impact on EA and PI. Reductions from baseline in MPFID scores indicate
`improvement.
`A total of 858 (90%) patients completed the 6-month double-blind study. Patients had a median age of 42 years
`(range: 18 to 65 years), 85% were female, and 89% were white. Three percent of patients were taking

`concomitant preventive treatments for migraine. The mean migraine frequency at baseline was approximately 8
`migraine days per month and was similar across treatment groups.

`AIMOVIG treatment demonstrated statistically significant improvements for key efficacy endpoints compared
`to placebo, as summarized in Table 3.
`

`
`Reference ID: 4264882
`
`
`

`Page 7 of 14
`
`7
`
`

`


`
`
`
`Table 3: Efficacy Endpoints Over Months 4 to 6 in Study 1
`
`
` AIMOVIG
`AIMOVIG
`
`70 mg Once Monthly
`
`140 mg Once Monthly
`N = 312
`N = 318
`
`
`-3.2
`
`-1.4
`< 0.001
`
`
`Monthly Migraine Days (MMD)
`
`
`Change from baseline
`Difference from placebo
`p-value
`
`≥ 50% MMD responders
`
`
`
`% Responders
`43.3%
`
`Difference from placebo
`16.7%
`Odds ratio relative to placebo
`2.1
`p-value
`< 0.001
`Monthly acute migraine-specific medication days
`
`
`
`-1.1
`Change from baseline
`
`Difference from placebo
`-0.9
`p-value
`< 0.001
`
`
`-3.7
`
`-1.9
`< 0.001
`
`
`50.0%
`
`23.4%
`2.8
`< 0.001
`
`
`-1.6
`
`-1.4
`< 0.001
`
`Placebo
`
`N = 316
`
`
`-1.8
`
`
`
`
`26.6%
`
`
`
`
`
`-0.2
`
`
`
`
`Figure 1: Change from Baseline in Monthly Migraine Days in Study 1a
`
`
`
` a Least-square means and 95% confidence intervals are presented.
`
`
`
`
`
`Figure 2 shows the distribution of change from baseline in mean monthly migraine days over months 4 to 6 in
`bins of 2 days by treatment group. A treatment benefit over placebo for both doses of AIMOVIG is seen across
`a range of changes from baseline in monthly migraine days.
`

`
`Reference ID: 4264882
`
`
`

`Page 8 of 14
`
`8
`
`

`


`
`Figure 2: Distribution of Change from Baseline in Mean Monthly Migraine Days over Months 4 to 6 by
`
`Treatment Group in Study 1
`
`
`Figure excludes patients with missing data.
`
`
`
`Compared to placebo, patients treated with AIMOVIG 70 mg once monthly and 140 mg once monthly showed
`greater reductions from baseline in mean monthly MPFID everyday activity scores averaged over months 4 to 6
`[difference from placebo: -2.2 for AIMOVIG 70 mg and -2.6 for AIMOVIG 140 mg; p-value < 0.001 for both],
`
`and in mean monthly MPFID physical impairment scores averaged over months 4 to 6 [difference from
`placebo: -1.9 for AIMOVIG 70 mg and -2.4 for AIMOVIG 140 mg; p-value < 0.001 for both].
`
`Study 2 (NCT 02483585) was a randomized, multi-center, 3-month, placebo-controlled, double-blind study
`evaluating AIMOVIG for the preventive treatment of episodic migraine. A total of 577 patients with a history of
`episodic migraine were randomized to receive either AIMOVIG 70 mg (N = 286) or placebo (N = 291) by
`subcutaneous injection once monthly for 3 months. Patients were allowed to use acute headache treatments
`including migraine-specific medications (i.e., triptans, ergotamine derivatives) and NSAIDs during the study.
`
`The study excluded patients with medication overuse headache as well as patients with myocardial infarction,
`stroke, transient ischemic attacks, unstable angina, coronary artery bypass surgery, or other revascularization
`procedures within 12 months prior to screening.
`
`The primary efficacy endpoint was the change from baseline in monthly migraine days at month 3. Secondary
`endpoints included the achievement of a ≥ 50% reduction from baseline in monthly migraine days (“≥ 50%
`MMD responders”), the change from baseline in monthly acute migraine-specific medication days at month 3,

`and the proportion of patients with at least a 5-point score reduction from baseline in MPFID at month 3.
`
`A total of 546 (95%) patients completed the 3-month double-blind study. Patients had a median age of 43 years
`(range: 18 to 65 years), 85% were female, and 90% were white. Six to seven percent of patients were taking
`concomitant preventive migraine treatment. The mean migraine frequency at baseline was approximately 8
`migraine days per month and was similar between treatment groups.
`
`AIMOVIG treatment demonstrated statistically significant improvements for key efficacy endpoints compared
`to placebo, as summarized in Table 4.
`

`
`Reference ID: 4264882
`
`
`

`Page 9 of 14
`
`9
`
`

`


`
`
`
`Table 4: Efficacy Endpoints at Month 3 for Study 2
`
` AIMOVIG
`70 mg Once Monthly
`N = 282
`
`
`Monthly Migraine Days (MMD)
`
`
`Change from baseline
`Difference from placebo
`p-value
`
`≥ 50% MMD responders
`
`
`% Responders
`Difference from placebo
`Odds ratio relative to placebo
`p-value
`Monthly acute migraine-specific medication days
`
`
`Change from baseline
`Difference from placebo
`p-value
`
`
`-2.9
`
`-1.0
`
`< 0.001
`
`
`39.7%
`
`10.2%
`1.6
`
`0.010
`
`
`-1.2
`
`-0.6
`
`0.002
`
`Placebo
`
`N = 288
`
`
`-1.8
`
`
`
`
`29.5%
`
`
`
`
`
`-0.6
`
`
`
`
`
`
`
`
`
` Figure 3: Change from Baseline in Monthly Migraine Days in Study 2a
`
`
`
`
`
` a Least-square means and 95% confidence intervals are presented.
`
`Figure 4 shows the distribution of change from baseline in monthly migraine days at month 3 in bins of 2 days
`
`by treatment group. A treatment benefit over placebo for AIMOVIG is seen across a range of changes from
`baseline in monthly migraine days.
`

`
`Reference ID: 4264882
`
`
`

`Page 10 of 14
`
`10
`
`

`


`
`Figure 4: Distribution of Change from Baseline in Monthly Migraine Days at Month 3 by Treatment
`
`Group in Study 2
`
`
`
`
`Figure excludes patients with missing data.
`
`The pre-specified analysis for the MPFID was based on at least a 5-point reduction within-patient responder
`definition. AIMOVIG 70 mg once monthly was not significantly better than placebo for the proportion of
`responders for everyday activity [difference from placebo: 4.7%; odds ratio = 1.2; p-value = 0.26] and physical
`impairment [difference from placebo: 5.9%; odds ratio = 1.3; p-value = 0.13]. In an exploratory analysis of the
`change from baseline in the mean MPFID scores at month 3, patients treated with AIMOVIG 70 mg, as
`
`compared to placebo, showed nominally greater reductions of physical impairment scores [difference from
`placebo: -1.3; p-value = 0.021], but not of everyday activities scores [difference from placebo: -1.1; p-value =
`0.061].
`
`Chronic Migraine
`Study 3 (NCT 02066415) was a randomized, multi-center, 3-month, placebo-controlled, double-blind study
`evaluating AIMOVIG as a preventive treatment of chronic migraine. A total of 667 patients with a history of
`chronic migraine with or without aura were randomized to receive AIMOVIG 70 mg (N = 191), AIMOVIG
`140 mg (N = 190), or placebo (N = 286) by subcutaneous injections once monthly for 3 months. Patients were
`allowed to use acute headache treatments including migraine-specific medications (i.e., triptans, ergotamine
`derivatives) and NSAIDs during the study.
`The study excluded patients with medication overuse headache caused by opiate overuse and patients with
`concurrent use of migraine preventive treatments. Patients with myocardial infarction, stroke, transient ischemic
`attacks, unstable angina, coronary artery bypass surgery, or other revascularization procedures within 12 months
`prior to screening were also excluded.
`
`The primary efficacy endpoint was the change from baseline in monthly migraine days at month 3. Secondary
`endpoints included the achievement of a ≥ 50% reduction from baseline in monthly migraine days (“≥ 50%
`MMD responders”) and change from baseline in monthly acute migraine-specific medication days at month 3.
`
`

`
`Reference ID: 4264882
`
`
`

`Page 11 of 14
`
`11
`
`

`


`A total of 631 (95%) patients completed the 3-month double-blind study. Patients had a median age of 43 years
`(range: 18 to 66 years), 83% were female, and 94% were white. The mean migraine frequency at baseline was
`approximately 18 migraine days per month and was similar across treatment groups.
`
`AIMOVIG treatment demonstrated statistically significant improvements for key efficacy outcomes compared
`to placebo, as summarized in Table 5.
`Table 5: Efficacy Endpoints at Month 3 in Study 3
`
`
` AIMOVIG
`AIMOVIG
`
`70 mg Once Monthly
`
`140 mg Once Monthly
`N = 188
`N = 187
`
`Placebo
`
`N = 281
`
`
`-6.6
`
`-2.5
`< 0.001
`
`
`41.2%
`
`17.7%
`2.3
`< 0.001
`
`
`-4.1
`
`-2.6
`< 0.001
`
`
`-4.2
`
`
`
`
`23.5%
`
`
`
`
`
`-1.6
`
`
`
`
`
`
`-6.6
`
`-2.5
`< 0.001
`
`
`Monthly Migraine Days (MMD)
`
`
`Change from baseline
`Difference from placebo
`p-value
`
`≥ 50% MMD responders
`
`
`
`% Responders
`39.9%
`
`Difference from placebo
`16.4%
`Odds ratio relative to placebo
`2.2
`p-value
`< 0.001
`Monthly acute migraine-specific medication days
`
`
`
`-3.5
`Change from baseline
`
`Difference from placebo
`-1.9
`p-value
`< 0.001
`
`
`

`
` Figure 5: Change from Baseline in Monthly Migraine Days in Study 3a
`
`
` a Least-square means and 95% confidence intervals are presented.
`
`
`
`
`
`
`

`Page 12 of 14
`
`Reference ID: 4264882
`
`12
`
`

`


`Figure 6 shows the distribution of change from baseline in monthly migraine days at month 3 in bins of 3 days
`by treatment group. A treatment benefit over placebo for both doses of AIMOVIG is seen across a range of
`changes from baseline in migraine days.
`
`
`Figure 6: Distribution of Change from Baseline in Monthly Migraine Days at Month 3 by Treatment
`Group in Study 3
`
`
`
`Figure excludes patients with missing data.
`
`
`16
`
`HOW SUPPLIED/STORAGE AND HANDLING
`
`
`16.1 How Supplied
`AIMOVIG (erenumab-aooe) injection is a sterile, clear to opalescent, colorless to light yellow solution for
`subcutaneous administration.
`
`The needle shield within the white cap of the AIMOVIG prefilled autoinjector and gray needle cap of the

`
`AIMOVIG prefilled syringe contain dry natural rubber (a derivative of latex). Each single-dose prefilled
`SureClick® autoinjector or single-dose prefilled syringe of AIMOVIG contains a Type 1 glass syringe and
`stainless steel needle and delivers 1 mL of 70 mg/mL solution.
`
`AIMOVIG is supplied as follows:
`
`SureClick® Autoinjector
`
`
` Pack of 1 autoinjector: 70 mg/mL single-dose prefilled autoinjector
`
`
`NDC 55513-841-01
` Pack of 2 autoinjectors: 140 mg/2 mL (2 x 70 mg/mL single-dose prefilled autoinjectors)
`
`
`NDC 55513-841-02
`Syringe
` Pack of 1 syringe: 70 mg/mL single-dose prefilled syringe
`
`
`NDC 55513-840-01
` Pack of 2 syringes: 140 mg/2 mL (2 x 70 mg/mL single-dose prefilled syringes)
`
`
`NDC 55513-840-02
`

`
`Reference ID: 4264882
`
`
`

`Page 13 of 14
`
`13
`
`

`


`
`16.2 Storage and Handling
`
` Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use.
`
`
`
`
` 
`
`If removed from the refrigerator, AIMOVIG should be kept at room temperature (up to 25°C [77°F]) in the
`original carton and must be used within 7 days. Throw away AIMOVIG that has been left at room
`temperature for more than 7 days.
`
` Do not freeze.
`
`
` Do not shake.
`
`
`
`17
`
`PATIENT COUNSELING INFORMATION
`
`Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
`
`Information on Preparation and Administration:
`
`Provide guidance to patients and caregivers on proper subcutaneous administration technique, including aseptic
`technique, and how to use the single-dose prefilled autoinjector or single-dose prefilled syringe [see Dosage
`and Administration (2.2)]. Instruct patients and/or caregivers to read and follow the Instructions for Use each
`time they use AIMOVIG.
`
`Instruct patients prescribed 140 mg to administer the once monthly dosage as two separate subcutaneous
`injections of 70 mg each.
`
`Advise latex-sensitive patients that the needle shield within the white cap of the AIMOVIG prefilled

`autoinjector and gray needle cap of the AIMOVIG prefilled syringe contain dry natural rubber (a derivative of
`latex) that may cause allergic reactions in individuals sensitive to latex [see Dosage and Administration (2.2)].
`
`For more information, go to www.aimovig.com or call 1-800-77-AMGEN (1-800-772-6436).
`
`
`
`
`
`AIMOVIG™ (erenumab-aooe)
`
`Manufactured by:
`
`Amgen Inc.
`
`One Amgen Center Drive
`
`Thousand Oaks, CA 91320-1799 USA
`
`U.S. License No. 1080
`
`Marketed by:
`
`Amgen Inc. (Thousand Oaks, CA 91320), and
`
`Novartis Pharmaceuticals Corporation (East Hanover, NJ 07936)
`
`
`Patent: http://pat.amgen.com/aimovig/
`
`
`© 2018 Amgen Inc. All rights reserved.
`
`v1
`
`
`
`

`
`Reference ID: 4264882
`
`
`

`Page 14 of 14
`
`14
`
`

`

`
`
`
`
` Patient Information
` AIMOVIGTM (AIM-oh-vig) (erenumab-aooe)
`
`
` injection, for subcutaneous use
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` What is AIMOVIG?
`
`
`
`
`
`
`
`
`
` AIMOVIG is a prescription medicine used for the preventive treatment of migraine in adults.
`
`
`
`
` It is not known if AIMOVIG is safe and effective in children under 18 years of age

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket